scholarly journals The added value of PSMA PET/MR radiomics for prostate cancer staging

Author(s):  
Esteban Lucas Solari ◽  
Andrei Gafita ◽  
Sylvia Schachoff ◽  
Borjana Bogdanović ◽  
Alberto Villagrán Asiares ◽  
...  

Abstract Purpose To evaluate the performance of combined PET and multiparametric MRI (mpMRI) radiomics for the group-wise prediction of postsurgical Gleason scores (psGSs) in primary prostate cancer (PCa) patients. Methods Patients with PCa, who underwent [68 Ga]Ga-PSMA-11 PET/MRI followed by radical prostatectomy, were included in this retrospective analysis (n = 101). Patients were grouped by psGS in three categories: ISUP grades 1–3, ISUP grade 4, and ISUP grade 5. mpMRI images included T1-weighted, T2-weighted, and apparent diffusion coefficient (ADC) map. Whole-prostate segmentations were performed on each modality, and image biomarker standardization initiative (IBSI)-compliant radiomic features were extracted. Nine support vector machine (SVM) models were trained: four single-modality radiomic models (PET, T1w, T2w, ADC); three PET + MRI double-modality models (PET + T1w, PET + T2w, PET + ADC), and two baseline models (one with patient data, one image-based) for comparison. A sixfold stratified cross-validation was performed, and balanced accuracies (bAcc) of the predictions of the best-performing models were reported and compared through Student’s t-tests. The predictions of the best-performing model were compared against biopsy GS (bGS). Results All radiomic models outperformed the baseline models. The best-performing (mean ± stdv [%]) single-modality model was the ADC model (76 ± 6%), although not significantly better (p > 0.05) than other single-modality models (T1w: 72 ± 3%, T2w: 73 ± 2%; PET: 75 ± 5%). The overall best-performing model combined PET + ADC radiomics (82 ± 5%). It significantly outperformed most other double-modality (PET + T1w: 74 ± 5%, p = 0.026; PET + T2w: 71 ± 4%, p = 0.003) and single-modality models (PET: p = 0.042; T1w: p = 0.002; T2w: p = 0.003), except the ADC-only model (p = 0.138). In this initial cohort, the PET + ADC model outperformed bGS overall (82.5% vs 72.4%) in the prediction of psGS. Conclusion All single- and double-modality models outperformed the baseline models, showing their potential in the prediction of GS, even with an unbalanced cohort. The best-performing model included PET + ADC radiomics, suggesting a complementary value of PSMA-PET and ADC radiomics.

Diagnostics ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 739
Author(s):  
Alessandro Bevilacqua ◽  
Margherita Mottola ◽  
Fabio Ferroni ◽  
Alice Rossi ◽  
Giampaolo Gavelli ◽  
...  

Predicting clinically significant prostate cancer (csPCa) is crucial in PCa management. 3T-magnetic resonance (MR) systems may have a novel role in quantitative imaging and early csPCa prediction, accordingly. In this study, we develop a radiomic model for predicting csPCa based solely on native b2000 diffusion weighted imaging (DWIb2000) and debate the effectiveness of apparent diffusion coefficient (ADC) in the same task. In total, 105 patients were retrospectively enrolled between January–November 2020, with confirmed csPCa or ncsPCa based on biopsy. DWIb2000 and ADC images acquired with a 3T-MRI were analyzed by computing 84 local first-order radiomic features (RFs). Two predictive models were built based on DWIb2000 and ADC, separately. Relevant RFs were selected through LASSO, a support vector machine (SVM) classifier was trained using repeated 3-fold cross validation (CV) and validated on a holdout set. The SVM models rely on a single couple of uncorrelated RFs (ρ < 0.15) selected through Wilcoxon rank-sum test (p ≤ 0.05) with Holm–Bonferroni correction. On the holdout set, while the ADC model yielded AUC = 0.76 (95% CI, 0.63–0.96), the DWIb2000 model reached AUC = 0.84 (95% CI, 0.63–0.90), with specificity = 75%, sensitivity = 90%, and informedness = 0.65. This study establishes the primary role of 3T-DWIb2000 in PCa quantitative analyses, whilst ADC can remain the leading sequence for detection.


2018 ◽  
Vol 123 (12) ◽  
pp. 952-965
Author(s):  
Simona Malaspina ◽  
Ugo De Giorgi ◽  
Jukka Kemppainen ◽  
Angelo Del Sole ◽  
Giovanni Paganelli

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Helle D. Zacho ◽  
Søren Ravn ◽  
Ali Afshar-Oromieh ◽  
Joan Fledelius ◽  
June A. Ejlersen ◽  
...  

2018 ◽  
Vol 21 (2) ◽  
pp. 204-211 ◽  
Author(s):  
I. Berger ◽  
C. Annabattula ◽  
J. Lewis ◽  
D. V. Shetty ◽  
J. Kam ◽  
...  

2017 ◽  
Vol 13 (20) ◽  
pp. 1801-1807 ◽  
Author(s):  
Niranjan J Sathianathen ◽  
Nicolas Geurts ◽  
Rajesh Nair ◽  
Nathan Lawrentschuk ◽  
Declan G Murphy ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Nikita Sushentsev ◽  
Leonardo Rundo ◽  
Oleg Blyuss ◽  
Vincent J. Gnanapragasam ◽  
Evis Sala ◽  
...  

AbstractNearly half of patients with prostate cancer (PCa) harbour low- or intermediate-risk disease considered suitable for active surveillance (AS). However, up to 44% of patients discontinue AS within the first five years, highlighting the unmet clinical need for robust baseline risk-stratification tools that enable timely and accurate prediction of tumour progression. In this proof-of-concept study, we sought to investigate the added value of MRI-derived radiomic features to standard-of-care clinical parameters for improving baseline prediction of PCa progression in AS patients. Tumour T2-weighted imaging (T2WI) and apparent diffusion coefficient radiomic features were extracted, with rigorous calibration and pre-processing methods applied to select the most robust features for predictive modelling. Following leave-one-out cross-validation, the addition of T2WI-derived radiomic features to clinical variables alone improved the area under the ROC curve for predicting progression from 0.61 (95% confidence interval [CI] 0.481–0.743) to 0.75 (95% CI 0.64–0.86). These exploratory findings demonstrate the potential benefit of MRI-derived radiomics to add incremental benefit to clinical data only models in the baseline prediction of PCa progression on AS, paving the way for future multicentre studies validating the proposed model and evaluating its impact on clinical outcomes.


2022 ◽  
Vol 63 (1) ◽  
pp. 69-75
Author(s):  
Ruohua Chen ◽  
Yining Wang ◽  
Yinjie Zhu ◽  
Yiping Shi ◽  
Lian Xu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document